Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial OpportunitiesGlobeNewsWire • 04/08/24
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare MeetingsGlobeNewsWire • 04/03/24
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/18/24
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare ProfessionalsGlobeNewsWire • 03/13/24
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18thGlobeNewsWire • 03/11/24
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular SurgeryGlobeNewsWire • 03/05/24
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing FacilityGlobeNewsWire • 02/13/24
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and CanadaGlobeNewsWire • 01/16/24
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/13/23
Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial ProductionGlobeNewsWire • 11/02/23
Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO's 51st Annual Continuing Education (ACE) ProgramGlobeNewsWire • 10/30/23
Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®GlobeNewsWire • 10/09/23
Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare ConferenceGlobeNewsWire • 09/21/23
Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/07/23